APLT's Govorestat Phase 3 Trial Results to be Presented at 2025 Conference | APLT Stock News

Author's Avatar
May 09, 2025
Article's Main Image

Applied Therapeutics (APLT, Financial) is set to present at the Peripheral Nerve Society's 2025 Annual Meeting, scheduled from May 17-20. The focal point of the presentation will be the full 12-month clinical outcomes from their INSPIRE Phase 3 trial of govorestat, also known as AT-007, aimed at treating SORD Deficiency, a subtype of Charcot-Marie-Tooth disease. Additionally, the event will highlight new topline data from 18 and 24-month periods. This follows their release of initial 12-month results back in February 2024.

Wall Street Analysts Forecast

1920951993954889728.png

Based on the one-year price targets offered by 4 analysts, the average target price for Applied Therapeutics Inc (APLT, Financial) is $2.88 with a high estimate of $5.00 and a low estimate of $1.50. The average target implies an upside of 619.29% from the current price of $0.40. More detailed estimate data can be found on the Applied Therapeutics Inc (APLT) Forecast page.

Based on the consensus recommendation from 5 brokerage firms, Applied Therapeutics Inc's (APLT, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.